Cele mai bune Biopharma podcast-uri (2023)

M

Medroots Biopharma India Private Limited

1
Inside the Pharma Franchise World: Navigating Opportunities with Medroots Bio Pharma 5:37

11d ago5:37

5:37

Discover the ever-changing world of pharmaceutical franchise opportunities with us on this insightful podcast episode. Learn about the tactics, difficulties, and accomplishments of Medroots Bio Pharma, a prominent figure in the sector. Discover the nuances of pharmaceutical franchises, the world of healthcare entrepreneurship, and how to succeed in…

P

Pathfinders in Biopharma

1
Raising Venture Capital: A New Playbook for A New Era in Biotech 36:19

11d ago36:19

36:19

In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal stru…

E

Evaluating Biopharma

1
Episode: 14 - Strategies and Approaches for Process Intensification With Dr. Stefan Schmidt 16:08

20d ago16:08

16:08

rocess intensification can be an overwhelming experience. In this episode of Evaluating Biopharma, host Ben Locwin speaks with Dr. Stefan Schmidt, CEO of evitria AG, about strategies and approaches that can help you understand and figure out how to navigate process intensification. Schmidt discusses ways to produce consistent results while using di…

D

Driving Digital in Biopharma

1
A modern balancing act: Harmonizing digital, data and traditional ways of working 43:10

1M ago43:10

43:10

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, speaks to Chris Braithwaite, Global Head of Drug Development, Digital and IT Novartis. Achieving digital transformation requires a delicate balance between traditional methods, rapidly emerging technology, and human decision-making. Chris encourages a shift in perspective…

P

Pathfinders in Biopharma

1
ECM: Robust End to Year, Despite Previous Volatility 31:24

1M ago31:24

31:24

As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of Healthcare Equity Capital Markets explore how the firms who succeed in an especially dynamic market will be those willing to embrace new ways of thinking about unlocking value.De către RBC Capital Markets

E

Evaluating Biopharma

1
Episode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar Khatwani 19:38

1M ago19:38

19:38

In this episode of Evaluating Biopharma, host Ben Locwin speaks with Santoshkumar Khatwani, Director – Analytical Development, Late-Stage CMC Analytical Team Lead at Sangamo Therapeutics, about impurities in gene therapy processes and the ways to identify them. Khatwani discusses how to determine if these impurities are from the product, the proces…

M

Medroots Biopharma India Private Limited

1
Medroots Bio Pharma Unlocks Opportunities in Healthcare 4:48

2M ago4:48

4:48

Explore the dynamic world of PCD Pharma Franchise in our podcast series. Dive into the pharmaceutical industry's entrepreneurial opportunities, success stories, and expert insights. Discover how to thrive as a PCD franchise partner, the latest healthcare trends, and the path to building a thriving pharmaceutical business. Join us for a dose of indu…

P

Pathfinders in Biopharma

1
Biotech Halftime Report: A Winding Road Ahead 17:26

2M ago17:26

17:26

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. This episode was originally broadcast on Industries in Motion, the RBC podcast.De către RBC Capital Markets

E

Evaluating Biopharma

1
Episode: 12 - The Risks and Rewards of Speed-to-IND Strategies With Susan Jones 19:32

3M ago19:32

19:32

What are some strategies that companies can use to get to IND filing quickly? In this brand new conversation, Evaluating Biopharma podcast host Ben Locwin discusses the risks and rewards of speed-to-IND strategies with Susan Jones, Chief Technology Officer at Tourmaline Bio. Susan delves into her 30 years of experience in the biotech industry, how …

P

Pathfinders in Biopharma

1
The Urgent Need to Address the Youth Mental Health Landscape 28:06

4M ago28:06

28:06

U.S. soccer legends and World Cup champions Briana Scurry and Dr. Sara Hess joined Andrew Callaway, Global Head of Healthcare Investment Banking at RBC Capital Markets, at this year’s RBC Global Healthcare Conference.De către RBC Capital Markets

E

Evaluating Biopharma

1
Episode: 11 - Cell Therapy Strategies: Preparing for Commercial Manufacturing of an Autologous Cell Therapy 21:49

4M ago21:49

21:49

In this episode of Evaluating Biopharma, host Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Jonathan Tsang, Senior Director, Manufacturing Sciences & Technology at Kite Pharma, who shares his experiences and provides advice on how autologous cell therapy companies can better prepare for commercial manufactur…

P

Pathfinders in Biopharma

1
Website Traffic Reveals Biopharma Sales Trends 10:39

4M ago10:39

10:39

A new RBC ElementsTM report, “Insights from the BioWeb,” looks at the predictive potential of website traffic as a means to uncover underappreciated market trends and sales insights. Mark Odendahl, Head of US Capital Markets Research, is joined by Brian Abrahams, Head of Biotechnology at RBC Capital Markets, to discuss the report’s findings.…

P

Pathfinders in Biopharma

1
When to Call it Quits: VCs Making Tough Decisions in a Tough Market 32:02

5M ago32:02

32:02

While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies ar…

E

Evaluating Biopharma

1
Episode: 10 - Gene Therapy Analytics: How to Make the Right CMC Investments for Your Business 22:43

5M ago22:43

22:43

In this episode of Evaluating Biopharma, Mike Kelly, Senior Vice President at Atsena Therapeutics, shares his experiences and provides his advice on how your company can make proper CMC investments to reduce risk and maximize ROI, including: the make or buy decision, ensuring CMC investment to provide regulators what they need, scalability consider…

P

Pathfinders in Biopharma

1
How Biotech M&A is Redefining the Strategic Landscape 25:53

5M ago25:53

25:53

Given current macro and regulatory headwinds, determining the optimal time to sell a biotech company is a multifaceted decision that requires careful consideration of several key factors. Hear from industry veterans Ted Love, Marc de Garidel, and Abbas Kazimi who share their insights on a new era of M&A in a panel moderated by RBC Capital Markets A…

E

Evaluating Biopharma

1
Episode: 9 - Gene Therapy Analytics: Identifying and Overcoming CMC Challenges in Gene Therapy 24:32

6M ago24:32

24:32

In this episode of Evaluating Biopharma, Ben Locwin, Vice President of Project Solutions at Black Diamond Networks, speaks with Susan D'Costa, Chief Technology Officer at Alcyone Therapeutics, who shares her experiences and provides advice on how your company can identify and overcome CMC challenges in gene therapy, including: understanding and mon…

P

Pathfinders in Biopharma

1
Healthcare Should Get Ready for ‘Fast and Furious’ M&A 26:06

6M ago26:06

26:06

Hear from Vito Sperduto, RBC’s Co-Head of Global M&A, and his panel of RBC Capital Markets’ expert bankers on how large healthcare firms with strong balance sheets are putting cash to work — driving a ‘fast and furious’ surge of M&A activity in the second half of the year and into 2024. Learn why healthcare momentum is building and how smaller deal…

P

Pathfinders in Biopharma

1
Innovation and Growth: Key Ingredients to Healthcare M&A 24:18

6M ago24:18

24:18

Compressed valuations, heightened CEO confidence, and the desire to accelerate top-line growth and scale innovation are the key factors driving healthcare M&A in 2023. As deal activity starts to accelerate, our banking experts are asking, what’s next for the sector? Listen to Pathfinders in Biopharma to find out. This episode features insights from…

P

Pathfinders in Biopharma

1
Biotech M&A Booms, But Have Buyouts Reached a Tipping Point? 17:04

6M ago17:04

17:04

In the latest episode of Pathfinders, Senior Biotechnology Analyst Gregory Renza discusses what’s driving the latest spate of biotech M&A activity — the new players and partnership dynamics that are creating what he calls “a landscape of competition” in the broader market.De către RBC Capital Markets

P

Pathfinders in Biopharma

1
Global Blood Therapeutics Commitment to Sickle-Cell Innovation 22:29

7M ago22:29

22:29

In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specif…

D

Driving Digital in Biopharma

1
Design for the future and deliver progress over perfection 41:43

7M ago41:43

41:43

In this episode of Driving Digital in Biopharma, Accenture host, Tom Lehmann, talks with Michel Rider, VP Digital, Analytics and Performance at GSK. Michel reflects on their multi-year quest to modernize digital, data, and analytics capabilities across Development – sharing insights for achieving near-term wins while planning for the future. There …

P

Pathfinders in Biopharma

1
Is This the Breakthrough Moment for Genetic Medicine? 17:25

8M ago17:25

17:25

Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of interven…

E

Evaluating Biopharma

1
Episode: 8 - The Financial Impact of a Continuous Bioprocessing Strategy 20:08

8M ago20:08

20:08

Joseph Shultz, VP and technical head of biologics and vaccines at Resilience, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss the financial considerations biopharma companies face when implementing a continuous strategy. Shultz talks about the mindset of the senior leadership at…

E

Evaluating Biopharma

1
Episode: 7 - Implementing an Efficient Allogeneic Cell Therapy Manufacturing Strategy 27:22

9M ago27:22

27:22

Marty Giedlin, vice president and head of technology operations at Senti Bio, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, to share his experiences and provide advice on how allogeneic cell therapy companies can implement better manufacturing strategies. He discusses understanding and managing man…

D

Driving Digital in Biopharma

1
Rethink it: Digital is not a thing, digital is a means 47:58

9M ago47:58

47:58

In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Jason Bronfeld, Head of Product Development IT at Bristol-Myers Squibb, about the industry re-perceiving itself and capitalizing on the power of digital. When it comes to evolving ways of operating to an ever-better model for the future, a mindset shift is essential – digi…

E

Evaluating Biopharma

1
Episode: 06 - Process Intensification: PAT, AI, ML to Support Intensified Bioprocessing 19:15

10M ago19:15

19:15

Arthi Narayanan, innovation team leader of pharma technical operations at Genentech, and John Bonham-Carter, board member and VP of business development and product management at Erbi Biosystems, discuss how process analytical technology, artificial intelligence, and machine learning support intensified bioprocessing and improve inefficiencies. Nar…

P

Pathfinders in Biopharma

1
The Hidden Revolution Set to Turn US Healthcare on its Head 19:07

10M ago19:07

19:07

In the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.De către RBC Capital Markets

E

Evaluating Biopharma

1
Episode: 05 - Navigating Scale-Up Challenges in Protein Production 20:45

11M ago20:45

20:45

Parrish Galliher, an independent bioprocess consultant, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the context-dependent issues that arise when scaling-up protein production. Gallaher uses a case study involving scaling challenges in E. coli bioprocesses that produced a product at 50% pote…

E

Evaluating Biopharma

1
Episode 4: Anticipating Disruptions: Identifying and Planning for Shortages 19:42

12M ago19:42

19:42

In the biopharma space, nearly every moving part is contingent upon a functioning supply chain. In this month’s episode, moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, speaks with Rich Musa, director and head of supply chain at Cipla Therapeutics, about anticipating supply chain disruptions and planning for sho…

P

Pathfinders in Biopharma

1
The Big Picture for Biotech 21:49

12M ago21:49

21:49

In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.De către RBC Capital Markets

D

Driving Digital in Biopharma

1
2022 Life Sciences Tech Trends - The Metaverse Continuum for Supply Chain 23:27

1y ago23:27

23:27

In this episode, Tom Lehmann talks with Natasha Kelly, a data scientist within Accenture's Applied Intelligence Group who focuses on advanced analytic solutions in life sciences manufacturing and supply chain. Tom and Natasha discuss the 2022 Life Sciences Technology Vision through a supply chain lens, delving into how each of the report's four tre…

P

Pathfinders in Biopharma

1
Why Biopharma Investment Requires a Different Mindset 22:52

1y ago22:52

22:52

In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.De către RBC Capital Markets

D

Driving Digital in Biopharma

1
2022 Life Sciences Tech Trends - The Metaverse Continuum for Biopharma R&D 14:19

1y ago14:19

14:19

In this episode, Tom Lehmann talks with Accenture’s Ross Wooddisse, Managing Director and Life Sciences R&D Lead in Europe, about the 2022 Life Sciences Technology Vision and what the Metaverse continuum means for Biopharma R&D. They discuss how science turns into medicine, a new generation of digital trial capabilities and the fundamental opportun…

E

Evaluating Biopharma

1
Episode: 3 - Cell and Gene Therapy: Managing the ‘Build or Buy’ Decision 22:36

1y ago22:36

22:36

Dave Backer, founder of DB Biologics and former chief commercial officer at Oxford Biomedica, speaks with moderator Ben Locwin, vice president of project solutions at Black Diamond Networks, about the complex business and technological decisions companies face when navigating supply chain issues in the cell and gene therapy (CGT) market. Today’s co…

E

Evaluating Biopharma

1
Episode: 2 - Operational Efficiencies: Lower Operational Costs by Reducing Clinical GMP Sampling 25:12

1y ago25:12

25:12

In this episode, Josefine Persson, Genentech associate director, and Ben Locwin, Black Diamond Networks vice president of project solutions, discuss how the cost of oversampling from clinical GMP runs versus development sources equates to high expenses and lost opportunities in moving a new project into GMP manufacturing. Persson also talks about t…

P

Pathfinders in Biopharma

1
The Optimism Behind the Biopharma Market 25:49

1y ago25:49

25:49

In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.De către RBC Capital Markets

E

Evaluating Biopharma

1
Episode 000: Introducing the Evaluating Biopharma Podcast 2:07

1y ago2:07

2:07

Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary informati…

E

Evaluating Biopharma

1
Episode 001: The Continuous Learning Curve: CPI’s Simon Hawdon on Process Conversion, Product Quality, and Platform Selection 21:53

1y ago21:53

21:53

In the inaugural episode of Evaluating Biopharma podcast, CPI’s Simon Hawdon speaks with Moderator John Bonham-Carter about the benefits of converting from batch to continuous processing and the critical decisions involved in making a high-quality product. Hawdon talks about whether there is an optimal time for process conversion, key equipment fea…

D

Driving Digital in Biopharma

1
2022 Life Sciences Tech Trends Overview 31:20

1y ago31:20

31:20

In this episode Tom Lehmann talks with Shalu Chada, Managing Director and Accenture’s Life Sciences Technology Lead, to discuss the 2022 Life Sciences Technology Vision and how each of the report's four trends ingrained in the metaverse are reshaping biopharma experiences of the future.De către Accenture

D

Driving Digital in Biopharma

1
Enabling tomorrow's science through digital 40:31

1+ y ago40:31

40:31

In this episode of Driving Digital in Biopharma, host Tom Lehmann talks with Anders Persson – Executive Director, Ecosystem Strategy & Innovation, AstraZeneca, about the role of digital and data in the transformation of global drug development and the value of an ecosystem and partnership strategy in R&D.…

D

Driving Digital in Biopharma

1
From documents to data - Regulatory's future? 40:43

1+ y ago40:43

40:43

Tom Lehmann and Eddie Reilly, Chief regulatory officer and head of global regulatory affairs, Sanofi discuss delivering new therapies to patients more efficiently and how that’s enabled by regulatory affairs - from standardizing data and harnessing AI to the more proficiently exchanging data with health authorities.…

D

Driving Digital in Biopharma

1
Raising the innovation bar in early research and development 38:31

1+ y ago38:31

38:31

Host Tom Lehmann talks with Lars Fogh Iversen, Senior Vice Present for Digital Science & Innovation at Novo Nordisk. They discuss the journey to accelerate research and early development through laboratory automation, data management, AI and digital research.De către Accenture

D

Driving Digital in Biopharma

1
Enabling scientific curiosity through digital in drug discovery 33:51

1+ y ago33:51

33:51

In Episode 11, host Tom Lehmann and guest Julie Huxley-Jones, GSK, discuss the mindset of scientific curiosity, innovation and collaboration and its role on the impact of digital in scientific discovery. They talk about the unique journey of digital in discovery research and how it’s increasing productivity and innovation.…

P

Pathfinders in Biopharma

1
Biotech Investors: How to Find Value in a Bear Market 28:55

1+ y ago28:55

28:55

How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy talks to HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia to find out.De către RBC Capital Markets

D

Driving Digital in Biopharma

1
Digital health and unlocking the value of data 39:59

2y ago39:59

39:59

Savyon Amit talks with Tom Lehmann about AstraZeneca's aligned understanding of Digital Health and the importance of articulating the value of digital from an organizational standpoint as well as value to the broader healthcare ecosystem.De către Accenture

D

Driving Digital in Biopharma

1
How a human health care philosophy is shaping a digital transformation 39:52

2y ago39:52

39:52

Tom Lehmann talks with Stephen Davies, VP, Eisai Enterprise Information Technology about Eisai’s human health care philosophy. It’s guiding innovation, shaping digital transformation and encouraging a holistic health care view by leveraging technology beyond traditional therapeutics.De către Accenture

P

Pathfinders in Biopharma

1
A call to action: Global Blood Therapeutics on tackling orphan disease 27:33

2y ago27:33

27:33

What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D., about having a mission and the drive to succeed on this episode of Pathfinders.De către RBC Capital Markets

D

Driving Digital in Biopharma

1
Data is the new currency for drug development 42:47

2y ago42:47

42:47

In this episode Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol-Myers Squibb talks with Tom Lehmann about the critical role of data, design and digital in the future vision for R&D.De către Accenture

P

Pathfinders in Biopharma

1
Ionis: Raising The Bar For ESG 23:46

2y ago23:46

23:46

In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.…

D

Driving Digital in Biopharma

1
Decentralized methods and the future of clinical research 46:08

2y ago46:08

46:08

Host Tom Lehmann talks with Craig Lipset, a long-time advocate and inspiring innovator in the clinical research and medicine development community. Drawing on his role as co-convenor of the Decentralized Trials and Research Alliance (DTRA), a collaboration of over 120 member organizations, Craig discusses DTRA’s ambitions and priorities for bringin…

Podcasturi care merită ascultate

Biopharma Podcast-uri

Podcasturi care merită ascultate

Ghid rapid de referință